Following on from information provided to NICE by the company in September 2020 the appraisal of Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 2700 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 December 2022 | Discontinued. Following on from information provided to NICE by the company in September 2020 the appraisal of Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 31 July 2020 | The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. Following an update from the company that market atezolizumab, NICE will not be progressing with the scoping exercise at this stage. The consultation on the draft scope will now close. Please accept our apologies for any inconvenience. |
For further information on our processes and methods, please see our CHTE processes and methods manual